The importance of quantifying the adverse effects on healthcare-related quality of life in people with benign gynecologic conditions
- PMID: 38983723
- PMCID: PMC11228797
- DOI: 10.1016/j.xfre.2024.03.003
The importance of quantifying the adverse effects on healthcare-related quality of life in people with benign gynecologic conditions
Conflict of interest statement
E.L.W. has nothing to disclose. L.B.C. reports funding from Oklahoma Shared Clinical and Translational Resource Institute NIGMS U54GM104938, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH/NICHD, Presbyterian Health Foundation, OU College of Medicine Alumni Association; honoraria and travel support from Ferring Pharmaceuticals; planned and pending patent: methods and compositions for treating diseases and conditions associated with gonadotropin-releasing hormone receptor." (Application: February 23, 2018); and a leadership role in the American Board of Obstetrics and Gynecology division of Reproductive Endocrinology & Infertility.
Comment on
References
-
- Wijeratne D., Gibson J.F.E., Fiander A., Rafii-Tabar E., Thakar R. The global burden of disease due to benign gynecological conditions: a call to action. Int J Gynecol Obstet. 2024;164:1151–1159. - PubMed
-
- Simoens S., Hummelshoj L., D’Hooghe T. Endometriosis: cost estimates and methodological perspective. Hum Reprod Update. 2007;13:395–404. - PubMed
-
- Huddleston H., Milani A., Blank R. Productivity loss due to polycystic ovary syndrome and its relationship to race, mental health and healthcare delivery indices. F&S Reports. 2024;5:157–163.
Publication types
LinkOut - more resources
Full Text Sources
